-
公开(公告)号：US11987851B2
公开(公告)日：2024-05-21
申请号：US17249896
申请日：2021-03-17
Applicant: Siemens Healthcare Diagnostics Inc.
Inventor： Arejas Uzgiris , Sunil Pandit , Lance Palmer
IPC: C12Q1/70
CPC classification number: C12Q1/707
Abstract: The present disclosure relates to oligonucleotide sequences for amplification primers and their use in performing nucleic acid amplifications of HCV, in particular regions that encode the NS3 polypeptide. In some embodiments the primers are used in nested PCR methods for the detection or sequencing of HCV NS3. The oligonucleotide sequences are also provided assembled as kits that can be used to amplify and detect or sequence HCV NS3.
-
公开(公告)号：US10053743B2
公开(公告)日：2018-08-21
申请号：US15367111
申请日：2016-12-01
Applicant: KAOHSIUNG MEDICAL UNIVERSITY
Inventor： Ming-Lung Yu , Wan-Long Chuang , Chia-Yen Dai , Jee-Fu Huang , Ming-Ying Lu , Edward Hsi
CPC classification number: C12Q1/707 , C12Q2600/106 , C12Q2600/158
Abstract: The present invention provides a method for predicting treatment efficacy of peginterferon plus ribavirin treatment in a subject suffering from chronic hepatitis C comprising: (a) measuring gene expression levels of genes comprising RSAD2, LOC26010, HERC5, HERC6, IFI44, SERPING1, IFITM3 and DDX60 of a blood sample from the subject after one week of the peginterferon plus ribavirin treatment; and (b) calculating a gene score according to cumulative fold change of the gene expression levels, when the gene score is equal to or higher than a cut-off value, the method predicts successful treatment of chronic hepatitis C with the peginterferon plus ribavirin treatment for the subject.
-
公开(公告)号：US10047406B2
公开(公告)日：2018-08-14
申请号：US14460180
申请日：2014-08-14
Applicant: Gen-Probe Incorporated
Inventor： Kui Gao , Edgar O. Ong , Jennifer Cole , Jeffrey M. Linnen
CPC classification number: C12Q1/707
Abstract: Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of Hepatitis E Virus (HEV) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
-
公开(公告)号：US20180223381A1
公开(公告)日：2018-08-09
申请号：US15881375
申请日：2018-01-26
Applicant: Theranos, Inc.
Inventor： Pranav Patel , Indira Wu , Aaron Richardson , Zahra Kamila Belhocine , Josephine Lee , Scott Tabakman
IPC: C12Q1/70 , C12Q1/6858
CPC classification number: C12Q1/707 , C12M1/00 , C12N15/00 , C12Q1/6844 , C12Q1/6858 , C12Q1/689 , C12Q1/706 , C12Q2600/156 , C12Q2600/158 , C12Q2521/501 , C12Q2525/161 , C12Q2525/307 , C12Q2531/113 , C12Q2531/119
Abstract: Methods and compositions for the identification of genetic-related information are provided. At least portions of methods provided herein may be performed without thermocycling. Methods and compositions may include reagents such as nucleic acid polymerases and primers.
-
公开(公告)号：US10036077B2
公开(公告)日：2018-07-31
申请号：US14597981
申请日：2015-01-15
Applicant: ABBOTT JAPAN CO., LTD. , TOKYO INSTITUTE OF TECHNOLOGY
Inventor： Ken Komiya , Makoto Komori , Toru Yoshimura
CPC classification number: C12Q1/707 , C12Q1/682 , C12Q1/6844 , C12Q1/689 , C12Q1/703 , C12Q1/706 , C12Q2600/158 , C12Q2600/178 , C12Q2521/301 , C12Q2525/301
Abstract: Disclosed are methods for detecting a target nucleic acid in sample, which include contacting the sample with an oligonucleotide having a hairpin structure, where the oligonucleotide includes, in the 5′ to 3′ direction, an arbitrary sequence, an endonuclease recognition site for a nicking reaction, a sequence complementary to the arbitrary sequence, and a sequence complementary to the target nucleic acid; a polymerase; and an endonuclease capable of nicking the endonuclease recognition site. The disclosure also provides compositions and kits comprising an oligonucleotide having a hairpin structure, where the oligonucleotide includes, in the 5′ to 3′ direction an arbitrary sequence, an endonuclease recognition site for a nicking reaction, a sequence complementary to the arbitrary sequence, and a sequence complementary to a target nucleic acid.
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20180148800A1
公开(公告)日：2018-05-31
申请号：US15367111
申请日：2016-12-01
Applicant: KAOHSIUNG MEDICAL UNIVERSITY
Inventor： Ming-Lung Yu , Wan-Long Chuang , Chia-Yen Dai , Jee-Fu Huang , Ming-Ying Lu , Edward Hsi
IPC: C12Q1/70
CPC classification number: C12Q1/707 , C12Q2600/106 , C12Q2600/158
Abstract: The present invention provides a method for predicting treatment efficacy of peginterferon plus ribavirin treatment in a subject suffering from chronic hepatitis C comprising: (a) measuring gene expression levels of genes comprising RSAD2, LOC26010, HERC5, HERC6, IFI44, SERPING1, IFITM3 and DDX60 of a blood sample from the subject after one week of the peginterferon plus ribavirin treatment; and (b) calculating a gene score according to cumulative fold change of the gene expression levels, when the gene score is equal to or higher than a cut-off value, the method predicts successful treatment of chronic hepatitis C with the peginterferon plus ribavirin treatment for the subject.
-
公开(公告)号：US09938590B2
公开(公告)日：2018-04-10
申请号：US13823551
申请日：2011-09-16
Applicant: Reinhold Pollner , Mehrdad Majlessi , Susan Yamagata , Michael M. Becker , Mark Reynolds , Lyle Arnold
Inventor： Reinhold Pollner , Mehrdad Majlessi , Susan Yamagata , Michael M. Becker , Mark Reynolds , Lyle Arnold
CPC classification number: C12Q1/707 , C12Q1/6837 , C12Q1/703 , Y02A50/53 , Y02A50/54 , C12Q2525/161
Abstract: The invention provides chimeric capture probes immobilizable via an L-nucleic acid tail that can bind to a complementary L-nucleic acid in an immobilized probe. The capture probes are useful for capturing a target nucleic acid from a sample. The L-nucleic acid in the tail of the capture probe bind to the complementary L-nucleic acid in the immobilized probe with similar affinity as would otherwise equivalent D-nucleic acids. However, the L-nucleic acid of the capture probe tail and immobilized probes do not form stable duplexes with D-nucleic acids present in the sample containing the target nucleic acid. Binding of nucleic acids in the sample directly to immobilized probe or to the tail of the capture probe is reduced or eliminated increasing the sensitivity and/or specificity of the assay.
-
公开(公告)号：US09909193B2
公开(公告)日：2018-03-06
申请号：US15087840
申请日：2016-03-31
Applicant: Theranos, Inc.
Inventor： Pranav Patel , Indira Wu , Aaron Richardson , Kamila Belhocine , Josephine Lee , Scott Tabakman
CPC classification number: C12Q1/707 , C12M1/00 , C12N15/00 , C12Q1/6844 , C12Q1/6858 , C12Q1/689 , C12Q1/706 , C12Q2600/156 , C12Q2600/158 , C12Q2521/501 , C12Q2525/161 , C12Q2525/307 , C12Q2531/113 , C12Q2531/119
Abstract: Methods and compositions for the identification of genetic-related information are provided. At least portions of methods provided herein may be performed without thermocycling. Methods and compositions may include reagents such as nucleic acid polymerases and primers.
-
9.发明授权公开(公告)号：US09879320B2
公开(公告)日：2018-01-30
申请号：US13983405
申请日：2012-02-09
Applicant: Ivan Bieche , Bénédicte Watelet , Tarik Asselah , Isabelle Catherine Batxelli , Eve Laure Mathieu , Nathalie Jullian , Michel Vidaud , Patrick Marcellin , Mohammad Afshar
Inventor： Ivan Bieche , Bénédicte Watelet , Tarik Asselah , Isabelle Catherine Batxelli , Eve Laure Mathieu , Nathalie Jullian , Michel Vidaud , Patrick Marcellin , Mohammad Afshar
CPC classification number: C12Q1/6876 , C12Q1/6883 , C12Q1/707 , C12Q2600/106 , C12Q2600/158 , G01N33/5767 , G01N2800/52
Abstract: The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being: at least one gene from among MBL2, LGALS3BP and IL8, and at least one gene from among G1P2, CCL21 and CXCL10, and optionally, at least one gene from among AFP, CRP, CXCL11, CXCL6, CXCL9, FGF7, MDK, MMP2, SFN, TGFB2 and VEGFD.
-
公开(公告)号：US09460268B2
公开(公告)日：2016-10-04
申请号：US14479245
申请日：2014-09-05
Applicant: Theranos, Inc.
Inventor： Elizabeth A. Holmes , Kamila Belhocine , Josephine Lee , Pranav Patel , Aaron Richardson , Scott Tabakman
IPC: G06F19/00 , C12Q1/70 , G01N33/569 , C12Q1/68
CPC classification number: G16H10/40 , C12Q1/68 , C12Q1/6806 , C12Q1/6844 , C12Q1/689 , C12Q1/6893 , C12Q1/6895 , C12Q1/70 , C12Q1/701 , C12Q1/703 , C12Q1/705 , C12Q1/706 , C12Q1/707 , C12Q2521/501 , C12Q2600/158 , C12Q2600/16 , G01N33/56911 , G01N33/56916 , G01N33/56938 , G01N33/56944 , G01N33/56983 , G01N33/56988 , G01N33/56994 , G01N35/10 , G01N2035/00237 , G01N2333/11 , G01N2469/10 , G01N2469/20 , G06F19/00 , G06F19/3456 , G16H20/10 , G16H50/20 , Y02A50/58 , Y02A90/24 , Y02A90/26 , Y10T436/11
Abstract: Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained.
Abstract translation: 提供了用于检测临床样品中的感染的系统，方法和装置。 在POS服务点（POS）位置获得的小批量临床样品，可在POS位置进行多种疾病包括上呼吸道疾病和下呼吸道疾病的多种标志物的检测。 可以测试样品的细胞因子或炎症指标。 样本的稀释或检测水平可以由受试者的状况或过去的历史来确定。 试样结果可以在试样放置在试验装置中之后的短时间内或在从受试者获得后的短时间内获得。 可以在POS位置提供用于治疗检测到的病症的处方，并且可以填充处方。 可以自动生成帐单用于测试，或者可以将处方自动发送给保险提供商，并且可以自动获得支付。
-
-
-
-
-
-
-
-
-
Search Results
545
records
(took 0.039 seconds)
